JP Morgan analyst Jessica Fye maintains BeiGene (NASDAQ:BGNE) with a Overweight and raises the price target from $194 to $200.
JP Morgan Maintains Overweight on BeiGene, Raises Price Target to $200
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.